|
|
Awards
Banquet
Tuesday, April 25, 2006
Time: 7:00 PM – 9:30 PM
Please join us for the centerpiece of our Conference, a
moving tribute to those individuals who have been nominated
and selected by their peers for extraordinary service in the
opioid treatment field. In 1983, Dr. Vincent Dole and Dr.
Marie Nyswander were the first recipients of this Award. The
Association continues to bestow this honor to individuals
who have devoted themselves to improving the lives of patients
in our treatment system.
The Nyswander / Dole Award: “Marie
Award” will be presented by Jerome Jaffe, MD
Dr. Jerome Jaffe is a psychiatrist and pharmacologist whose
work in the area of addiction spans treatment, basic and clinical
research, teaching, writing, policy, and government service.
From 1971 to 1973, Dr. Jaffe served as the first Director
of Special Action Office for Drug Abuse Prevention at the
White House, which formed the basis for current efforts in
drug abuse research and treatment. Dr. Jaffe is currently
a clinical professor of psychiatry at University of Maryland
School of Medicine and an adjunct professor at Johns Hopkins
University School of Hygiene and Public Health.
The 2006 American Association for the Treatment of Opioid
Dependence National Conference recognizes outstanding contributions
to methadone treatment by rewarding the Nyswander/Dole Award
to the following individuals:
M. Douglas Anglin, PhD
California
Dr. M. Douglas Anglin is the Associate Director of the UCLA
Integrated Substance Abuse Program in the Department of Psychiatry
and Biobehavioral Sciences at the University of California.
Dr. Anglin produced one of the earliest and most comprehensive
bodies of work supporting the efficacy of methadone treatment.
He has been a facilitator in the development of many coalitions.
His research has provided powerful documentation to use with
policy makers, funding agencies, administrators, and clinicians.
He is described as a visionary, dedicated, unrepentant workaholic,
brilliant, creative, wicked wit, playful and irreverent; and
a born net worker before the term was used.
Andrew
Byrne, MD
Australia
Dr. Andrew Byrne is an addiction medicine specialist in Redfern,
Australia which is a disadvantaged inner city area. He has
been a strong advocate for methadone treatment for over eighteen
years. Dr. Byrne has been a strong supporter and mentor for
other doctors. He is an assiduous provider of information
about methadone treatment and other related fields to a large
and growing international electronic network. He has for many
years been active in organizing continuing education for doctors
and other clinicians working with drug addiction. Dr. Byrne
provides both methadone treatment
and primary health care to his patients.
John Chappel, MD
Nevada
Dr. John Chappel is the Medical Director of the American Therapeutic
Association Methadone Clinic in Sparks, Nevada and Professor
Emeritus at the University of Nevada Medical School. For the
35 years he has advocated for methadone treatment. He has
been involved in physician training for attending and resident
physicians. In 1990 he received the ASAM Award in Physician
Education and Certification. He has been involved in methadone
treatment since 1986 and has co-authored articles with Dr.
Jerome Jaffe and Dr. Loretta Finnegan. Dr. Chappel is described
as a person who is kind,
unassuming, and eloquent who exhibits great care when seeing
patients.
Don C. DesJarlais, PhD
New York
Dr. Don DesJarlais is the Director of the Baron Edmond de
Rothschild Chemical Dependency Institute at Beth Israel Medical
Center, a Research Fellow with the National Development and
Research Institutes, Inc. and Professor of Epidemiology with
the Department of Epidemiology and Population Health of Albert
Einstein College of Medicine. He has published over 425 articles
and conducted over 1,500 presentations. He consistently helps
the field understand the psychological and social aspect of
the disease. His work has demonstrated conclusively and compellingly
that treatment of opiate dependence is an absolute necessity
in the face of the HIV crisis.
James S. Dorsey, MD
Maryland
Dr. James S. Dorsey is the Medical Director of the Adult Addiction
Opioid Program of the Anne Arundel County Department of Health.
Through his efforts he ensured the continuation and expansion
of medication assisted treatment. He continually seeks opportunities
to educate; patients, politicians, community leaders, local
and national health care providers on the efficacy of medication-assisted
treatment. As a researcher and clinician he has made a significant
contribution to the body of literature in the areas of pain
anagement in methadone patients and in optimum dose levels.
He is a strong
promoter of “science to service” and evidence based
practices.
David A. Fiellin, MD
Connecticut
Dr. David A. Fiellin is an Associate professor of Medicine
at Yale University and a Robert Wood Johnson Generalist Physician
Faculty Scholar. His extensive scholarly work is focused on
the interface between primary care and substance abuse. He
has published several key articles on methadone patient treatment
in medicine’s best journals. He conducts research on
the transfer of treatment strategies, including opioid agonist
maintenance with methadone and buprenorphine, from specialized
settings to office-based, primary care, and HIV specialty
settings. He is a role model of the highest standard for trainees
in medicine including medical students, residents, fellows
and junior faculty.
William
B. Miller, MD
Pennsylvania
Dr. William B. Miller is the Medical Director of TADISO, Inc.
Responding to the growing heroin epidemic and mindful of the
controversies surrounding methadone treatment and community
resistance, Dr. Miller opened a clinic in 1969 in one of Pittsburgh’s
toughest neighborhoods. At the age of 83 with 36 years of
service he continues to provide treatment in a quiet understated
manner devoid of negativism and judgment. Recognized by his
peers, his career is a testament to those who first embraced
methadone as a valued treatment for addiction to opiates.
A recipient of many awards, he continues to serve 650 patients.
Lubomir Okruhlica, MD
Slovak Republic
Dr. Lubomir Okruhlica is the Director of the Centre for Treatment
of Drug Dependencies in Bratislava of the Slovak Republic.
He established the first maintenance program in Slovakia,
at first with codeine. Later on he established the methadone
maintenance treatment program at the Centre for Treatment
of Drug Dependencies in Bratislava 1997. Dr. Okruhlica is
in charge of a central, specialized health institution for
treatment and research of health related problems associated
with psychoactive substance use, predominantly for dependencies.
He is actively involved in the international cooperation and
organization of the field, especially in the Central European
region.
Tyrone Patterson, CAC-II
Washington, DC
Tyrone Patterson is the Manager of Addiction Prevention and
Recovery Administration Model Treatment Clinic in Washington,
DC. Mr. Patterson has been providing dedicated service to
methadone patients for over 30 years. Model Treatment under
Mr. Patterson’s able leadership was one of the first
methadone CARF certified clinics. His command of the theoretical
and the practical provision of substance abuse services have
served to further the legitimacy of District of Columbia methadone
treatment programs. Mr. Patterson is a champion of compassionate
treatment for opiate addicts. Mr.
Patterson is described by his colleges as an efficient and
effective manager and leader.
Jina Thalmann, LSCW
Florida
Jina Thalmann is the Program Director of the Opioid Dependency
Treatment Program in Orlando, Florida. Ms. Thalmann has been
a leader in the field for the treatment of opiate dependency
in the correctional setting. She took the lead in 2001 by
developing the Methadone Program for the Orange County Jail
in Orlando, Florida. Because of her work Orlando has the only
residential program in Central Florida that allows methadone
maintenance patients to participate in their program. Additionally,
her work with the Drug Court has impacted the practice of
allowing patients in Drug Court to be on methadone or buprenorphine.
Terry Willis, MS
Georgia
Terry Willis is Chairman of the Board of the Opioid Treatment
Providers of Georgia and CEO of Georgia Therapy Associates,
Inc. When Terry became Chairman of the OTPG, the state of
Georgia and the treatment providers were in an adversarial
relationship. Terry’s efforts broke down the atmosphere
of distrust. He forged a partnership whereas the State officials
and treatment providers are working partners. The adversarial
to advocacy concept has paved the way for grants for the study
of HIV and Hepatitis testing. We are here tonight because
of Terry’s tireless efforts to bring this great conference
to this great city.
FRIEND OF THE FIELD AWARD
The prestigious Friend of the Field Award was established
by the American Association for the Treatment of Opioid Dependence
Board of Directors. This award recognizes extraordinary contributions
to the field of methadone treatment by an individual or institution
whose work, although not directly related to methadone treatment,
has had a significant impact on our field. The 2006 Friend
of the Field Award has been awarded to:
Kimberly A. Johnson, MS Maine
Director, Maine Office of Substance Abuse
Ms. Kimberly Johnson serves as the Director of the Maine Office
of Substance Abuse. She has been an indefatigable advocate
of methadone treatment programs in Maine during a turbulent
period of development. Maine did not have methadone treatment
programs within its boundaries until 1995. Ms. Johnson has
provided extraordinary and consistent leadership in resisting
the efforts of community groups and elected officials in closing
methadone treatment programs in addition to fending off legislation,
which would have had a negative impact on the evolution of
methadone treatment programs in Maine and the Northeaster
corridor. Ms. Johnson also has the distinction of being the
only State Alcohol and Drug Abuse Director to spearhead a
major public relations campaign, through radio and other media
outlets, to specifically support the methadone treatment system.
The continued use of methadone treatment in Maine would have
been seriously threatened were it not for Ms. Johnson’s
leadership in the face of such extraordinary challenge.
Supported
through a Grant from Mallinckrodt, Inc.
|
